194726-46-0

Basic information

• Product Name: (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE
• Synonyms: (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE;(R)-tert-butyl 3-formylpiperidine-1-carboxylate;tert-butyl (3R)-3-forMylpiperidine-1-carboxylate;ert-Butyl (3R)-3-formylpiperidine-1-carboxylate;tert-Butyl (R)-3-formylpiperidine-1-carboxylate;(R)-1-Boc-3-piperidinecarboxaldehyde;(R)-1-Boc-3-formyl-piperidine
• CAS NO: 194726-46-0
• Molecular Formula: C₁₁H₁₉NO₃
• Molecular Weight: 213.28
• Mol File: 194726-46-0.mol

Chemical Properties

• Appearance: /
• Density: 1.114
• Storage Temp.: Inert atmosphere,Store in freezer, under -20°C
• CAS DataBase Reference: (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE(CAS DataBase Reference)
• NIST Chemistry Reference: (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE(194726-46-0)
• EPA Substance Registry System: (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE(194726-46-0)

Safety Data

• Hazardous Substances Data: 194726-46-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research:
(R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE is used as a key intermediate in the synthesis of various pharmaceuticals and bioactive molecules. Its importance as a building block in medicinal chemistry is attributed to its ability to facilitate the creation of a wide range of functionalized piperidine derivatives for diverse biological and pharmaceutical applications.
Used in Organic Synthesis:
In the field of organic synthesis, (R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE serves as a versatile starting material. Its unique structure and the Boc protecting group enable the preparation of a broad spectrum of functionalized piperidine derivatives, which are essential for various applications in the chemical and pharmaceutical industries.
Used in Peptide Synthesis:
(R)-1-(TERT-BUTOXYCARBONYL)-3-PIPERIDINECARBOXALDEHYDE is utilized as a protecting agent for amine groups in peptide synthesis. The Boc group provides a stable and easily removable protection, ensuring the successful synthesis of complex peptide structures without unwanted side reactions or degradation.

Upstream product

• 194726-40-4 (3R)-piperidine-1,3-dicarboxylic acid 1-tert-butyl ester 3-ethyl ester 
• 24424-99-5 di-tert-butyl dicarbonate 
• 116574-71-1 tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 934423-10-6 1-(tert-butyl)-3-methyl-(R)-piperidine-1,3-dicarboxylate 
• 33741-15-0 methyl (4E)-hepta-4,6-dienoate 
• 79280-39-0 (4E)-hepta-4,6-dienal 
• 651321-53-8 Benzyl-[(E)-hepta-4,6-dien-(E)-ylidene]-amine 
• 445398-78-7 N-benzyl-hepta-4(E),6-dien-1-amine 

Downstream Products

• 254905-64-1 (3S)-3-(dimethylaminomethyl)piperidine-1-carboxylic acid tert-butyl ester 
• 894801-73-1 benzyl 4-{[(3S)-1-(tert-butoxycarbonyl)piperidin-3-yl]methyl}piperazine-1-carboxylate 
• 894802-13-2 tert-butyl (3S)-3-[(4-{[(3,4-dichlorophenyl)amino]carbonyl}piperazin-1-yl)methyl]piperidine-1-carboxylate 
• 116574-71-1 tert-butyl (3R)-3-(hydroxymethyl)piperidine-1-carboxylate 
• 1381949-95-6 C₂₃H₃₆N₄O₄ 
• 1381949-83-2 C₂₁H₂₉N₅O 
• 1381949-82-1 C₂₁H₂₉N₅O 
• 1381949-81-0 C₂₁H₃₂N₄O₂ 
• 894799-72-5 C₂₀H₂₉ClN₄O 
• 894799-08-7 N-(3,4-dichlorophenyl)-4-[(3R)-piperidin-3-ylmethyl]piperazine-1-carboxamide 

Relevant articles and documents

NON-LYSOSOMAL GLUCOSYLCERAMIDASE INHIBITORS AND USES THEREOF

The invention provides compounds for inhibiting glucosylceramidases, prodrugs of the compounds, and pharmaceutical compositions including the compounds or prodrugs of the compounds.

Facile synthesis of 7-alkyl-1,2,3,4-tetrahydro-1,8-naphthyridines as arginine mimetics using a Horner-Wadsworth-Emmons-based approach

Integrin inhibitors based on the tripeptide sequence Arg-Gly-Asp (RGD) are potential therapeutics for the treatment of idiopathic pulmonary fibrosis (IPF). Herein, we describe an expeditious three-step synthetic sequence of Horner-Wadsworth-Emmons olefination, diimide reduction, and global deprotection to synthesise cores for these compounds in high yields (63-83% over 3 steps) with no need for chromatography. Key to this transformation is the phosphoramidate protecting group, which is stable to metalation steps.

TEAD INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Palladium-catalyzed ring-closing reaction via C-N bond metathesis for rapid construction of saturated N-heterocycles

The ring-closing reactions based on chemical bond metathesis enable the efficient construction of a wide variety of cyclic systems which receive broad interest from medicinal and organic communities. However, the analogous reaction with C-N bond metathesis as a strategic fundamental step remains an unanswered challenge. Herein, we report the design of a new fundamental metallic C-N bond metathesis reaction that enables the palladium-catalyzed ring-closing reaction of aminodienes with aminals. The reactions proceed efficiently under mild conditions and exhibit broad substrate generality and functional group compatibility, leading to a wide variety of 5- to 16-membered N-heterocycles bearing diverse frameworks and functional groups.

AZOLE-SUBSTITUTED PYRIDINE COMPOUND

The present invention provides a compound represented by formula [I'| shown below or a pharmaceutically acceptable salt thereof that has an inhibitory effect on 20-HETE producing enzyme, wherein the structure represented by formula [III] shown below represents any of the structures represented by formula group [IV] shown below, wherein R1 represents a hydrogen atom, a fluorine atom, methyl, etc.; R2, R3, and R4 each independently represent a hydrogen atom, a fluorine atom, or methyl; W represents a single bond, C1-3alkanediyl, or the formula -O-CH2CH2-; and ring A represents (a) substituted C4-6cycloalkyl, (b) substituted 4- to 6-membered saturated nitrogen-containing heterocyclyl, (c) substituted phenyl, (d) substituted pyridyl, (e) substituted 2,3-dihydrobenzofuran, (f) 4- to 6-membered saturated oxygen-containing heterocyclyl, etc.

Benzimidazole-2-piperazine compound, its pharmaceutical composition and its preparation and use

The invention relates to a benzimidazole-2-piperazine derivative and a preparing method and application of the benzimidazole-2-piperazine derivative in medicine, in particular to a novel benzimidazole-2-piperazine derivative shown in the general formula (I), a preparing method of the derivative, a pharmaceutical composition containing the derivative and application of the derivative serving as a therapeutic agent, especially serving as a poly (ADP-ribose) polymerase (PARP) inhibitor. In the general formula (I), R refers to hydrogen or halogen, G refers to carbonyl or methylene, m is 1-2, n is 1-3, and Q refers to hydrogen or C1-C4 alkyl. When X is methylene and Y is NR1 or methylene, X is NR1; R1 refers to hydrogen, C1-C6 alkyl, benzyl, COR2 or SO2R2; R2 refers to the following groups which are not substituted or groups substituted by 1-3 substituent groups, including C1-C6 alkyl, C3-C8 naphthenic base, phenyl, benzyl, naphthyl and C5-C10 aromatic heterocycle base, heterocycle in the C5-C10 aromatic heterocycle base comprises 1-3 heteroatoms selected from N, O and S, and the substituent groups are selected from the following atoms or groups of C1-C6 alkyl, C1-C6 alkoxy, halogen, amidogen, nitryl, sulfydryl, hydroxyl, cyanogroup and trifluoromethyl. The general formula (I) is shown in the specification.

NOVEL COMPOUNDS THAT ARE ERK INHIBITORS

Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof, wherein: A is a five membered monocyclic heteroaryl ring; and B is a monocyclic heterocycloalkyl ring, or a monocyclic heterocycloalkenyl ring, or a bridge

The design and synthesis of novel, potent and orally bioavailable N-aryl piperazine-1-carboxamide CCR2 antagonists with very high hERG selectivity

A novel N-aryl piperazine-1-carboxamide series of human CCR2 chemokine receptor antagonists was discovered. Early analogues were potent at CCR2 but also inhibited the hERG cardiac ion channel. Structural modifications which decreased lipophilicity and basicity resulted in the identification of a sub-series with an improved margin over hERG. The pharmacological and pharmacokinetic properties of the lead compound from this series, N-(3,4-dichlorophenyl)-4-[(2R)-4-isopropylpiperazine-2-carbonyl] piperazine-1-carboxamide, are described.

Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning

Compounds having the formula wherein the symbols have the meaning described in the specification are hydroxamic acid derivatives of 4-phenyl-4-hydroxy-butyric acid and capable of inhibiting the lethal effects of infection by anthrax bacteria and are usefu

4-Piperidines and 3-pyrrolidines as dual serotonin and noradrenaline reuptake inhibitors: Design, synthesis and structure-activity relationships

Single enantiomer [(aryloxy)(pyridinyl)methyl]piperidine and pyrrolidine derivatives 5-9 are inhibitors of monoamine reuptake. Structure-activity relationships established that monoamine reuptake inhibition are functions of amine, pyridine isomer, aryloxy ring substitution and stereochemistry. Consequently, selective NRIs, selective SRIs, dual SNRIs and triple SNDRIs were all identified. Dual SNRIs 5l-a and 9c were evaluated in additional pharmacology and pharmacokinetic studies as representative examples from this series.